Provided is an agent for reducing odors of pyrazine derivatives based on an olfactory receptor antagonism. The agent for reducing odors of pyrazine derivatives includes at least one antagonist of olfactory receptor OR5K1 as an active ingredient.

The present invention provides compositions and methods for treating a dermatological disorder or disease.

The present invention provides compositions and methods for treating a dermatological disorder or disease.

The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.

The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.

Methods and systems for performing 3-D LIDAR measurements of objects simultaneously illuminated by two or more beams of light in the far field are described herein. A 3-D LIDAR based measurement device simultaneously emits at least two beams of light into a three dimensional environment from different locations. A portion of the three dimensional environment is simultaneously illuminated by the two or more light beams at a distance of at least five meters from the LIDAR device. However, the two or more light beams do not overlap at a distance less than five meters from the LIDAR device. The beams of light are slightly divergent, having highest intensity at the device and steadily lower intensity further away. By overlapping illumination beams in the far field, but not near the LIDAR device, overall intensity is maintained at moderate levels throughout the field of view of the LIDAR device.

Methods and systems for performing 3-D LIDAR measurements of objects simultaneously illuminated by two or more beams of light in the far field are described herein. A 3-D LIDAR based measurement device simultaneously emits at least two beams of light into a three dimensional environment from different locations. A portion of the three dimensional environment is simultaneously illuminated by the two or more light beams at a distance of at least five meters from the LIDAR device. However, the two or more light beams do not overlap at a distance less than five meters from the LIDAR device. The beams of light are slightly divergent, having highest intensity at the device and steadily lower intensity further away. By overlapping illumination beams in the far field, but not near the LIDAR device, overall intensity is maintained at moderate levels throughout the field of view of the LIDAR device.

A balm mixture is provided for treating dry eyes. The balm mixture is applied from a container to the skin of the user adjacent their lower eyelid. The balm mixture includes a carrier portion and an active ingredient portion which will cause tears to form in the eye of a user adjacent the application thereof, thereby alleviating a dry eye condition.

A balm mixture is provided for treating dry eyes. The balm mixture is applied from a container to the skin of the user adjacent their lower eyelid. The balm mixture includes a carrier portion and an active ingredient portion which will cause tears to form in the eye of a user adjacent the application thereof, thereby alleviating a dry eye condition.

A method of treating haematological cancer with a therapy comprising a DHODH inhibitor. Also provided is a combination therapy comprising a pan-HER inhibitor and a DHODH inhibitor for treating a haematological cancer.